The Generics Bulletin Top 50, Part Two: Mid-Table Movements See Firms Jostle For Position

Some Companies Climb As Others Slip Down Rankings

 
• By Dave Wallace
  
Generate a summary of this article
Listen to this article
Beta

Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.

Generics Bulletin Top 50 2022
Mid-table companies have moved in various directions • Source: Shutterstock

With the significant movements seen among the 10 leading companies in Generics Bulletin’s Top 50 this year nevertheless leaving the ranking order of firms at the very top of that top-10 table undisturbed, a similar trend can be observed in the second part of our rundown, covering positions 11-30. (Also see "The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations" - Generics Bulletin, 15 August, 2022.)

Compared to last year, the same five companies lead off this second table, in the same order – with Cipla,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Company Rankings

More from Market Intelligence